Vestitol

Vestitol: A Comprehensive Encyclopedic Reference

1. Identity: Chemical Name, Classification, and Natural Sources

1.1 Chemical Identity and Nomenclature

Vestitol is formally identified as (3S)-7,2′-dihydroxy-4′-methoxyisoflavan, bearing the CAS registry number 56701-24-7 for the racemic (±) form. It belongs to the isoflavan subclass of the isoflavonoid family of polyphenolic phytochemicals. Isoflavans are 5-deoxyisoflavonoids first discovered in legumes; vestitol is classified alongside glabridin (from licorice, Glycyrrhiza glabra) and sativan from Lotus japonicus, alfalfa, and other species.

Vestitol exists as two enantiomers. Vestitol (the base compound) is the R-isomer, while (+)-vestitol, also known as (3S)-vestitol, is the S-isomer. In scientific literature, (3S)-vestitol and (−)-vestitol are the forms most frequently studied in the context of biological activity. The compound possesses a chroman-like bicyclic backbone featuring two hydroxyl groups (at the 7 and 2′ positions) and one methoxy group (at the 4′ position), distinguishing it from related isoflavans such as sativan, which carries an additional methoxy group at the 2′ position.

1.2 Botanical and Natural Sources

Vestitol is a phytoalexin — a stress-induced secondary metabolite produced by plants in response to environmental challenge — distributed across a range of leguminous plants (family Fabaceae). The isoflavan (−)-vestitol, biosynthesized by the reduction of (−)-medicarpin, is the major phytoalexin in Lotus species.

Key botanical sources identified in peer-reviewed literature include:

• Lotus japonicus and related Lotus species: An isoflavan vestitol is a phytoalexin of the Lotus spp. including the model legume Lotus japonicus.
• Lotus corniculatus (birdsfoot trefoil): Two phytoalexins, (−)-sativan and (−)-vestitol [(−)-7,2′-dihydroxy-4′-methoxyisoflavan], were induced by a spore suspension of Helminthosporium turcicum.
• Lotus hispidus (hairy birdsfoot trefoil): A new isoflavonoid phytoalexin isolated from the fungus-inoculated leaflets of Lotus hispidus has been identified as 5-methoxyvestitol; three known isoflavans including vestitol are also produced by L. hispidus.
• Lotus pedunculatus (greater birdsfoot trefoil): Identified as a root source of vestitol, with documented insect feeding-deterrent activity.
• Trifolium arvense (hare's-foot clover): Vestitol is a compound isolated from the leaves of Trifolium arvense.
• Machaerium vestitum: The wood of Machaerium vestitum contains (+)-vestitol [(3S)-7,2′-dihydroxy-4-methoxyisoflavan] alongside formononetin, (+)-medicarpin, and (−)-mucronulatol.
• Dalbergia ecastaphyllum (L.) Taub. (Fabaceae): The role of Dalbergia ecastaphyllum (L.) Taub. (Fabaceae) as the main botanical source of Brazilian red propolis has been previously confirmed. The results of phytochemical and chromatographic analyses confirmed D. ecastaphyllum as the botanical source of vestitol (among other isoflavonoids including neovestitol, medicarpin, and formononetin).

The synthesis of vestitol in Lotus sp. is notably induced by ultraviolet (UV) radiation and the attachment of the root parasitic plant Striga hermonthica; pterocarpan reductase (PTR) catalyzes this process, utilizing medicarpin as a substrate.

1.3 Vestitol in Brazilian Red Propolis

While vestitol is a plant phytoalexin, it has gained the most scientific attention as a bioactive constituent of Brazilian red propolis (BRP). Brazilian red propolis is produced by Apis mellifera bees and originates mainly in the coastal region of Maceió city, Alagoas state; its botanical origin is the resin of Dalbergia ecastaphyllum, and its main constituents are isoflavonoids and flavonoids, especially formononetin, vestitol, and neovestitol.

Studies confirmed the presence of a rich variety of phenolic compounds in both the propolis and the plant resin, such as chalcones (e.g., isoliquiritigenin), flavonoids (e.g., luteolin, liquiritigenin), isoflavones (e.g., formononetin, biochanin A), isoflavans (e.g., vestitol, neovestitol, 7-O-methylvestitol), pterocarpanes (e.g., medicarpin, homopterocarpin, vesticarpan), and C30 isoflavans (retusapurpurins A and B). GC-MS analysis of the purified neovestitol-vestitol (NV) bioactive fraction from red propolis established that neovestitol comprised 60.4% and vestitol 27.6% of the NV fraction.

1.4 Common Forms and Preparations

Vestitol is encountered in research and applied contexts in the following forms:

• Ethanolic (hydroalcoholic) extracts of Brazilian red propolis: The most widely studied form, prepared by extracting raw propolis in ethanol or ethanol/water mixtures.
• Purified neovestitol-vestitol (NV) fractions: Using bioassay-guided fractionation coupled with spectroscopic analysis, a highly purified neovestitol and vestitol-containing bioactive fraction (NV) was isolated from red propolis.
• Isolated (3S)-vestitol: Used in mechanistic laboratory studies; obtained by extraction and chromatographic purification from plant or propolis sources.
• Propolis-containing oral health formulations: Topical applications including varnishes and rinses evaluated preclinically for dental use.
• Research-grade chemical reagents: Pure (±)-vestitol, (−)-vestitol, and (+)-vestitol are available from chemical suppliers for laboratory investigation only.

---

2. Traditional and Historical Use

Vestitol as an isolated, identified molecule has no documented pre-modern history of use; it was first isolated and characterized as a phytoalexin in the second half of the twentieth century. Its traditional history is therefore inseparable from the traditions surrounding the plants and bee products from which it is derived.

2.1 Propolis in Traditional Medicine

Propolis is a honeybee product used extensively in traditional medicine across many cultures, including in South America, Eastern Europe, Asia, and the Middle East. Indigenous and traditional communities in northeastern Brazil have long used red propolis preparations for their antimicrobial and wound-healing properties, though formal ethnobotanical documentation of specific preparations made from BRP predates modern chemical isolation of vestitol.

2.2 Leguminous Plants Containing Vestitol

Birdsfoot trefoil (Lotus corniculatus) and related legumes have been cultivated and used in traditional European and Mediterranean agricultural and pastoral systems primarily as fodder plants, not as medicinal preparations in human use. Vestitol's biological role in these plants was identified as a phytoalexin with insect feeding-deterrent activity (J Chem Ecol 4, 571–579, 1978). Machaerium vestitum, native to Brazil, is used in traditional Brazilian folk medicine, though documented uses specifically attributable to its vestitol content have not been established in the scientific literature reviewed.

2.3 Ecological and Plant Defense Role

In its natural context, vestitol functions as a phytoalexin — a defense chemical synthesized on demand. Pterocarpan reductase (PTR) catalyzes vestitol's biosynthesis from medicarpin; vestitol subsequently undergoes methylation by O-methyltransferase to produce sativan, another phytoalexin that accumulates significantly upon fungal pathogen infection in alfalfa and Lotus sp. Its role in plant defense against fungal pathogens and insect herbivores is well-documented in the ecological literature, but this represents the plant's defensive chemistry rather than intentional human use.

---

3. Biosynthesis, Key Constituents, and Mechanisms of Action

3.1 Biosynthesis of Vestitol

(−)-Vestitol and (−)-sativan are typical isoflavan phytoalexins produced by leguminous plants including the model legume L. japonicus; earlier studies suggested a close biosynthetic relationship between isoflavan and pterocarpan, with interconversion of the pterocarpan medicarpin and the isoflavan vestitol demonstrated by feeding ¹⁴C-labeled precursors to alfalfa seedlings.

EST databases of L. japonicus were mined for PCBER-like SDR sequences, and four clones (PTR1–PTR4) homologous to phenylcoumaran benzylic ether reductase were isolated; the recombinant proteins (PTR1–PTR4) catalyzed the formation of vestitol from medicarpin in the presence of NADPH.

Formononetin, 2′,7-dihydroxy-4′-methoxyisoflavone, 7-hydroxy-4′-methoxyisoflavanone, and 2′,7-dihydroxy-4′-methoxyisoflavanone are excellent precursors of vestitol and related phytoalexins, suggesting that a metabolic grid may be involved in their biosynthetic origin.

3.2 Co-occurring Compounds in Brazilian Red Propolis

When studying vestitol in the context of BRP, it is important to note the co-occurrence of closely related bioactive isoflavans. The main constituents of Brazilian red propolis include isoflavonoids formononetin, liquiritigenin, vestitol, neovestitol, biochanin A, and medicarpin, as well as isoliquiritigenin, which is a chalcone. Two bioactive isoflavonoids (vestitol and neovestitol) and a chalcone (isoliquiritigenin) were identified in Brazilian propolis, out of which isoliquiritigenin was found to be the most active against Staphylococcus aureus.

3.3 Established Mechanisms of Anti-Inflammatory Action

The most thoroughly investigated mechanism of vestitol concerns its modulation of the innate immune response, particularly neutrophil migration and macrophage function.

Neutrophil chemokine suppression: Pre-treatment with vestitol at 1, 3, or 10 mg/kg reduced LPS- or mBSA-induced neutrophil migration and the release of CXCL1/KC and CXCL2/MIP-2 in vivo; likewise, pre-treatment with vestitol at 1, 3, or 10 μM reduced the levels of CXCL1/KC and CXCL2/MIP-2 in macrophage supernatants in vitro. Moreover, the administration of vestitol (10 mg/kg) reduced leukocyte rolling and adherence in the mesenteric microcirculation of mice.

Nitric oxide suppression: Vestitol inhibited NO production by 83% at 0.55 μM without affecting cell viability compared to the vehicle control (P < 0.05).

Cytokine modulation: Treatment with vestitol reduced GM-CSF, IL-6, TNF-α, IL-4, and TGF-β levels and increased IL-10 release (P < 0.05).

NF-κB pathway inhibition: (3S)-vestitol at 0.55 µM lowered NO release by 60% without altering cell viability and diminished IL-1β, IL-1α, G-CSF, IL-10 and GM-CSF levels; it reduced expression of Icam-1, Wnt5a, and Mmp7 (associated with inflammation and tissue destruction in periodontitis) and increased expression of Socs3 and Dab2 genes (inhibitors of cytokine signaling and NF-κB pathway).

Macrophage polarization: Vestitol diminished the activation of NF-κB and Erk 1/2 pathways and induced macrophages into M2-like polarization.

Broad pathway modulation: Vestitol affected the expression of genes related to the NF-κB pathway, NO synthase, and inhibition of leukocyte transmigration, namely: Ccs, Ccng1, Calm1, Tnfsf15, Il11, Gata3, Gadd45b, Cdkn1b, Csf1, Ccl5, Birc3 (negatively regulated), and Igf1 (positively regulated).

Anti-cancer molecular target: Vestitol, a Brazilian red propolis bioactive isoflavonoid, down-regulates the alpha-tubulin, tubulin in microtubules, and histone H3 genes; alpha-tubulin and tubulin in microtubules move descendant chromosomes in cell division during mitosis, and the disruption of microtubules may affect the progression of the cancer cell cycle.

Multi-pathway scope: Vestitol, among other isolated compounds from BRP, has demonstrated the ability to modulate critical pro-inflammatory signaling pathways, including NF-κB, TLR4, JAK/STAT, and PI3K/AKT, while concurrently activating antioxidant and cytoprotective responses via the Nrf2/HO-1 axis. These effects are further supported by the suppression of pro-inflammatory cytokines, regulation of immune cell infiltration and activation, inhibition of inflammasome components such as NLRP3, induction of autophagy, and polarization of macrophages and microglia from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype.

3.4 Antioxidant Activity

Vestitol (39.5%) showed better antioxidant potential in inhibiting β-carotene consumption in vitro than neovestitol (21.4%) in a comparative assay of isolated isoflavonoids from red propolis.

---

4. Scientific Evidence by Area of Use

Important note on evidence strength: At the time of writing, vestitol has not been the subject of any registered human clinical trials as an isolated, defined supplement ingredient. All evidence described below derives from in vitro (cell-culture) and in vivo (animal model) research, plus a small number of laboratory studies using the purified NV (neovestitol-vestitol) fraction in rodent models. Evidence must therefore be characterized as preliminary and preclinical throughout. No authoritative regulatory body (NIH ODS, EMA, EFSA, or WHO) has issued a formal monograph or evaluation for vestitol as a supplement ingredient.

4.1 Anti-Inflammatory Activity

Study type and evidence level: In vitro and in vivo (rodent); preliminary.

The objective of key early research was to evaluate anti-inflammatory and antimicrobial activities of neovestitol and vestitol isolated from Brazilian red propolis (BRP), with BRP ethanolic extract, neovestitol, and vestitol evaluated for anti-inflammatory properties using a neutrophil migration assay. Neovestitol, vestitol, and EEP inhibited neutrophil migration at a dose of 10 mg/kg.

A dedicated mechanistic study published in the Journal of Natural Products (2016) focused specifically on vestitol's effect on neutrophil migration. Pre-treatment with vestitol at 1, 3, or 10 mg/kg reduced LPS- or mBSA-induced neutrophil migration and the release of CXCL1/KC and CXCL2/MIP-2 in vivo; pre-treatment with vestitol at 1, 3, or 10 μM reduced the levels of CXCL1/KC and CXCL2/MIP-2 in macrophage supernatants in vitro.

A 2022 study in Pharmaceuticals elucidated (3S)-vestitol's mechanisms in macrophages. Peritoneal macrophages of C57BL6 mice, stimulated with lipopolysaccharide, were treated with 0.37 to 0.59 µM of (3S)-vestitol for 48 h, after which nitric oxide quantities, macrophage viability, the release of 20 cytokines, and the transcription of several genes related to cytokine production and inflammatory response were evaluated. The conclusion was that (3S)-vestitol anti-inflammatory mechanisms involve cytokines and NF-κB pathway inhibition.

Intraperitoneal administration of vestitol or neovestitol (10 mg/kg) in murine models significantly reduced neutrophil migration, with efficacy comparable to dexamethasone (1 mg/kg); these effects were linked to the modulation of inflammatory mediators, decreased leukocyte rolling and adhesion, and, in the case of neovestitol, nitric oxide-dependent mechanisms.

Limitations: All studies are in animal (murine) models or cell culture. No human clinical studies have tested vestitol for inflammatory conditions. Effective doses used in animal models cannot be directly extrapolated to human dosing. The comparison with dexamethasone is from an animal model and should not be interpreted as equivalence in humans.

4.2 Oral Health: Anti-Caries and Antibiofilm Activity

Study type and evidence level: In vitro and in vivo (rodent); moderate preclinical consistency.

The most replicated area of vestitol research concerns its activity against Streptococcus mutans and oral biofilm. A pivotal study examined the NV fraction against S. mutans biofilm formation. Topical applications of NV (800 μg/mL) significantly impaired the accumulation of S. mutans biofilms by largely disrupting the synthesis of glucosyltransferase-derived exopolysaccharides and the expression of genes associated with the adaptive stress response, such as copYAZ and sloA. Of even greater impact, NV was as effective as fluoride (positive control) in reducing the development of carious lesions in vivo. The in vivo component used a rodent model of dental caries.

Topical application for five weeks (800 μg/mL, twice daily) reduced the development of carious lesions in the rat model of dental caries.

A 2024 study extended this research to periodontitis-associated multispecies biofilm. The aim was to evaluate the effect of the combination of neovestitol–vestitol (CNV) compounds obtained from Brazilian red propolis on the microbiological profile of a mature multispecies subgingival biofilm comprising 32 bacterial species formed for seven days; treatment with CNV (1600, 800, 400, and 200 μg/mL), amoxicillin (54 μg/mL), and vehicle control was performed for 24 h on the last day of biofilm formation. The highest tested concentration (1600 μg/mL) was even more effective than amoxicillin treatment, reducing the amount of 25 species compared to vehicle control and 13 species compared to amoxicillin-treated biofilms; it appears that amoxicillin is a non-selective antibiotic acting on both health- and disease-associated bacteria, while CNV has a prominent effect on disease-associated species.

A 2025 follow-up study similarly assessed the NV fraction on a 33-species subgingival biofilm model. The 33-species biofilm was formed for seven days using a Calgary device; starting on day 3, treatments were applied twice daily for 1 min each: NV (400–1,600 μg/mL), chlorhexidine 0.12% (as positive control), or vehicle.

Limitations: All oral health studies use in vitro biofilm systems or rodent caries models. No randomized controlled human trials have been conducted. The effective concentrations (800–1600 μg/mL) are applied topically, and systemic absorption is not studied in these contexts. The NV fraction contains both neovestitol and vestitol; the contribution of each compound individually versus their combination is not always disaggregated in the literature.

4.3 Antimicrobial Activity

Study type and evidence level: In vitro; preliminary.

The antimicrobial activity of neovestitol and vestitol was evaluated by minimal inhibitory and bactericidal concentrations (MIC and MBC) against Streptococcus mutans, Streptococcus sobrinus, Staphylococcus aureus, and Actinomyces naeslundii; vestitol showed MICs ranging from 25–50 to 50–100 μg/mL and MBCs ranging from 25–50 to 50–100 μg/mL. Neovestitol demonstrated somewhat lower (more potent) MIC values, with MICs ranging from <6.25 to 25–50 μg/mL against the same organisms.

Chromatographic analysis of Brazilian red propolis crude extract confirmed the presence of isoflavanes (vestitol, neovestitol, 7-O-methylvestitol), pterocarpans (medicarpin), and polyprenylated acylphloroglucinols as main compounds of the BRP. These compounds were also evaluated for anti-periodontopathogenic and antiviral activity in in vitro models.

Limitations: All antimicrobial data are from in vitro broth microdilution or disk diffusion assays. In vitro MIC values do not reliably predict clinical efficacy. No pharmacokinetic data confirming that therapeutic concentrations of vestitol reach target tissues in humans are available.

4.4 Potential Anticancer Activity

Study type and evidence level: In vitro molecular; very preliminary.

Vestitol down-regulates alpha-tubulin, tubulin in microtubules, and histone H3 genes; alpha-tubulin and tubulin in microtubules move descendant chromosomes in cell division during mitosis, and the disruption of microtubules may affect the progression of the cancer cell cycle.

Vestitol and neovestitol stand out as multifunctional phytochemicals with therapeutic potential in inflammatory and neoplastic diseases, capable of modulating critical signaling pathways and showing selective cytotoxicity toward tumor cells; these findings support their candidacy as natural lead compounds for the development of novel anti-inflammatory and anticancer agents and warrant further investigation into their pharmacodynamics and molecular targets.

Limitations: Anticancer claims rest entirely on in vitro molecular biology and cell culture data. No animal tumor models specifically testing isolated vestitol as an anticancer agent were identified in the reviewed literature. No human data exist. This area of evidence is highly preliminary and speculative in terms of clinical translation.

4.5 Antioxidant Activity

Study type and evidence level: In vitro assay; preliminary.

Vestitol's antioxidant potential has been measured primarily using the β-carotene bleaching inhibition assay and compared with co-occurring propolis compounds. Vestitol (39.5%) demonstrated better antioxidant potential in inhibiting β-carotene consumption in vitro than neovestitol (21.4%). However, these are in vitro chemical assays of radical-scavenging capacity and do not demonstrate antioxidant effects in biological systems or humans.

---

5. Body Systems and Health Areas of Association

Based on the peer-reviewed literature available, vestitol has been associated — at a preclinical level — with the following body systems and health areas:

• Immune system / Inflammation: Inhibition of neutrophil chemotaxis and migration; modulation of macrophage polarization (M1 to M2 shift); suppression of pro-inflammatory chemokines (CXCL1/KC and CXCL2/MIP-2) and cytokines (IL-1β, IL-1α, GM-CSF, IL-6, TNF-α).
• Oral health: Anti-biofilm and anti-caries activity against Streptococcus mutans and periodontitis-associated subgingival pathogens including Porphyromonas gingivalis and Tannerella forsythia.
• Antimicrobial defense: Direct antibacterial activity against oral and skin pathogens including S. aureus and Actinomyces naeslundii.
• Oncology (preclinical only): Modulation of cell-cycle regulatory proteins (alpha-tubulin, histone H3) and cytotoxic effects in cancer cell lines.
• Oxidative stress: In vitro radical-scavenging and antioxidant capacity.
• Cardiovascular-adjacent (molecular): Reduced expression of Scd1 and Scd2 genes (correlated to atherosclerosis) in macrophage models, though this observation is molecular and has not been translated into cardiovascular endpoint research.

---

6. Dosage Forms and Dosages Reported in Studies

The following dosages are reported as used in the cited scientific studies. They are not recommendations and have not been validated in human clinical trials.

• In vivo (rodent, intraperitoneal), anti-inflammatory studies: Vestitol at 1, 3, or 10 mg/kg (body weight) reduced LPS- or mBSA-induced neutrophil migration and chemokine release.
• In vivo anti-inflammatory, comparison with dexamethasone: Intraperitoneal administration of vestitol or neovestitol at 10 mg/kg in murine models significantly reduced neutrophil migration, with efficacy comparable to dexamethasone (1 mg/kg).
• In vitro, macrophage studies: (3S)-vestitol at 0.37 to 0.59 µM was used to treat LPS-stimulated peritoneal macrophages for 48 h.
• In vitro, NO inhibition: Vestitol inhibited NO production by 83% at 0.55 µM.
• In vitro, neutrophil migration: Pre-treatment with vestitol at 1, 3, or 10 μM reduced the levels of CXCL1/KC and CXCL2/MIP-2 in macrophage supernatants.
• Topical, anti-caries (rodent model): The chemical sub-fraction containing vestitol and neovestitol was applied topically for five weeks (800 μg/mL, twice daily) and reduced the development of carious lesions in the rat model of dental caries.
• In vitro, periodontitis-related multispecies biofilm: Treatment with CNV (neovestitol-vestitol combination) at 1600, 800, 400, and 200 μg/mL was performed for 24 h.
• Antimicrobial (in vitro MIC): Vestitol showed MICs ranging from 25–50 to 50–100 μg/mL and MBCs ranging from 25–50 to 50–100 μg/mL against tested oral bacteria.

---

7. Safety Considerations and Interactions

7.1 Toxicology Data

Preliminary data suggest that vestitol and neovestitol possess low toxicity; acute and sub-acute oral toxicity studies of Brazilian red propolis, which contains these compounds, have not reported significant adverse effects in rats, indicating a relatively safe profile. However, these assessments apply to Brazilian red propolis as a whole product and cannot be directly extrapolated to isolated vestitol at higher or different doses.

The extracts of D. ecastaphyllum stem showed the presence of pterocarpanes, isoflavanes, isoflavones, and chalcones presenting similarities with Brazilian red propolis extract; medicarpin, vestitol, and neovestitol are the major compounds in stem extract of D. ecastaphyllum. Non-clinical toxicological evaluations have been conducted on the hydroalcoholic extract of D. ecastaphyllum stems, with the action on genomic instability and colon carcinogenesis also investigated in that context, though detailed published results were not available in the sources reviewed.

7.2 Cell Viability

At 0.55 µM, vestitol inhibited NO production without affecting cell viability in macrophage cell models, suggesting a selective pharmacological effect at those concentrations rather than non-specific cytotoxicity. Studies consistently tested and reported cell viability alongside pharmacological effects.

7.3 Research-Stage Compound Status

Vestitol as an isolated compound is classified by chemical reagent suppliers explicitly as being for research use only and not for sale to patients or for human use. It has not received regulatory approval as a pharmaceutical or dietary supplement ingredient by any reviewed regulatory authority. No formal drug interaction studies, clinical pharmacokinetic data, maximum tolerated dose assessments in humans, or long-term toxicity studies of isolated vestitol are available in the peer-reviewed literature at this time.

7.4 Considerations Specific to Propolis-Containing Products

Since vestitol is most commonly encountered as a constituent of Brazilian red propolis preparations, the established safety profile of propolis is relevant context. Propolis is known to cause allergic reactions in susceptible individuals, particularly those with bee-product sensitivities or balsam-of-Peru allergy. These propolis-related risks are not specifically attributable to vestitol itself, as they likely arise from multiple propolis constituents. Individuals with known sensitivities to bee products or legume-derived materials should be aware that BRP contains numerous isoflavonoids including vestitol.

7.5 Absence of Interaction Data

No peer-reviewed studies specifically examining vestitol's interactions with pharmaceutical drugs, hormones, or other dietary supplements have been identified in the sources reviewed. Given vestitol's structural similarity to phytoestrogenic isoflavonoids and its demonstrated modulation of NF-κB and cytokine signaling, interactions with immunosuppressant medications or hormone-sensitive conditions are theoretically plausible but remain uncharacterized in the published scientific record.

---

Summary of Evidence Strength

As of the date of this article, the scientific evidence for vestitol's biological activities is entirely preclinical. Research demonstrates consistent and mechanistically coherent anti-inflammatory effects in rodent models and in vitro systems, with the anti-caries and anti-periodontitis biofilm data being particularly reproducible across multiple research groups in Brazil. Antimicrobial activity has been established in vitro against clinically relevant oral bacteria. Antioxidant and putative anticancer activities remain at the level of chemical assays and molecular cell studies. These findings support the candidacy of vestitol as a natural lead compound for the development of novel anti-inflammatory and anticancer agents and warrant further investigation into its pharmacodynamics and molecular targets, but human clinical validation is entirely lacking at this time.

References

• Bueno-Silva B et al. (2013). Anti-Inflammatory and Antimicrobial Evaluation of Neovestitol and Vestitol Isolated from Brazilian Red Propolis. Journal of Agricultural and Food Chemistry, 61(19), 4546–4550.
• Franchin M et al. (2016). Vestitol Isolated from Brazilian Red Propolis Inhibits Neutrophils Migration in the Inflammatory Process: Elucidation of the Mechanism of Action. Journal of Natural Products, 79, 954–960.
• Bueno-Silva B et al. (2022). Anti-Inflammatory Effects of (3S)-Vestitol on Peritoneal Macrophages. Pharmaceuticals, 15(5), 553.
• Bueno-Silva B et al. (2022). Anti-Inflammatory Effects of (3S)-Vestitol on Peritoneal Macrophages. PMC Full Text.
• Bueno-Silva B et al. (2013). Effect of neovestitol-vestitol containing Brazilian red propolis on accumulation of biofilm in vitro and development of dental caries in vivo. Biofouling, 29, 1233–1242. PubMed.
• Bueno-Silva B et al. (2013). Effect of Neovestitol-vestitol containing Brazilian red propolis on biofilm accumulation in vitro and dental caries development in vivo. PMC Full Text.
• Macedo TT et al. (2024). Combination of Neovestitol and Vestitol Modifies the Profile of Periodontitis-Related Subgingival Multispecies Biofilm. Biomedicines, 12(6), 1189. PMC Full Text.
• Macedo TT et al. (2024). Combination of Neovestitol and Vestitol Modifies the Profile of Periodontitis-Related Subgingival Multispecies Biofilm. Biomedicines.
• Franchin M et al. (2016). Neovestitol, an isoflavonoid isolated from Brazilian red propolis, reduces acute and chronic inflammation: involvement of nitric oxide and IL-6. Scientific Reports, 6, 36401.
• Franchin M et al. (2016). Neovestitol, an isoflavonoid isolated from Brazilian red propolis, reduces acute and chronic inflammation. PMC Full Text.
• Aldana-Mejía JA et al. (2020). Dalbergia ecastaphyllum (L.) Taub. and Symphonia globulifera L.f.: The Botanical Sources of Isoflavonoids and Benzophenones in Brazilian Red Propolis. Molecules, 25(9), 2060. PMC Full Text.
• Aldana-Mejía JA et al. (2020). Dalbergia ecastaphyllum (L.) Taub. and Symphonia globulifera L.f.: The Botanical Sources of Isoflavonoids and Benzophenones in Brazilian Red Propolis. Molecules.
• Frontiers in Plant Science (2024). Biosynthesis and metabolic engineering of isoflavonoids in model plants and crops: a review.
• Mori T et al. (2017). The Missing Link in Leguminous Pterocarpan Biosynthesis is a Dirigent Domain-Containing Protein with Isoflavanol Dehydratase Activity. PMC Full Text.
• Mori T et al. (2017). Missing Link in Leguminous Pterocarpan Biosynthesis is a Dirigent Domain-Containing Protein with Isoflavanol Dehydratase Activity. Plant and Cell Physiology, 58(2), 398.
• ScienceDirect Topics: Vestitol — Overview.
• Ollis WD et al. (1978). Vestitol and vesticarpan, isoflavonoids from Machaerium vestitum. Phytochemistry.
• Bonde MR, Millar RL, Ingham JL (1973). Induction and identification of sativan and vestitol as two phytoalexins from Lotus corniculatus. Phytochemistry, 12, 2957–2959.
• Russell GB et al. (1978). Vestitol: A phytoalexin with insect feeding-deterrent activity. Journal of Chemical Ecology, 4, 571–579.
• Phytochemicals from Brazilian Red Propolis: A Review of Their Anti-Inflammatory Potential. Plants, 2025, 14(19), 2961.
• Phytochemicals from Brazilian Red Propolis: A Review of Their Anti-Inflammatory Potential. PMC Full Text.
• Anticancer Activity of Propolis and Its Compounds. PMC Full Text.
• Potential in vitro anti-periodontopathogenic, anti-Chikungunya activities and in vivo toxicity of Brazilian red propolis. PMC Full Text.
• Toxicological and chemoprevention studies of Dalbergia ecastaphyllum (L.) Taub. stem, the botanical source of Brazilian red propolis. Journal of Pharmacy and Pharmacology, 74(5), 740.
• Food-grade delivery systems of Brazilian propolis from Apis mellifera: From chemical composition to bioactivities in vivo. Food Chemistry, 2023.
• Combination of neovestitol and vestitol impair the subgingival multispecies biofilm development. Biofouling, 2025.
• Akashi T et al. (2006). Identification of Lotus japonicus cDNAs encoding pterocarpan reductase, the final enzyme of the isoflavan phytoalexin biosynthesis. CiNii Research.